Document is current
Any future updates will be listed below
-
Authors
Villette, Rémy
Ortís Sunyer, Júlia
Novikova, Polina V.
Aho, Velma T. E.
Petrov, Viacheslav A.
Hickl, Oskar
Busi, Susheel Bhanu
De Rudder, Charlotte
Kunath, Benoit J.
Heintz-Buschart, Anna
Trezzi, Jean-Pierre
Halder, Rashi
Jäger, Christian
Lebrun, Laura A.
Daujeumont, Annegrät
Schade, Sebastian
Janzen, Annette
Jehmlich, Nico
von Bergen, Martin
Laczny, Cédric C.
May, Patrick
Trenkwalder, Claudia
Oertel, Wolfgang
Mollenhauer, Brit
Wilmes, Paul
-
Funding
Funding for this research was provided by:
HORIZON EUROPE European Research Council (863664)
Fonds National de la Recherche Luxembourg (PRIDE/11823097, CORE/16/BM/11333923, CORE/15/BM/10404093, FNR11264123)
Michael J. Fox Foundation for Parkinson's Research (MJFF-019228)
Institute for Advanced Studies, Université of Luxembourg (MCI-BIOME_2019)
European Union’s Horizon 2020 Widening Fellowships (101038088)
DFG Research Unit FOR2488 (INTER/DFG/19/14429377)
Rotary Club Luxembourg
- License Information
-
More Information
Article History
Received: 3 February 2025
Accepted: 11 August 2025
First Online: 7 October 2025
Declarations
:
: The study conformed to the Declaration of Helsinki and was approved by the ethics committee of the Physician’s Board Hessen, Germany (FF 89/2008). The DeNoPa trial is registered at the German Register for Clinical trials (DRKS00000540).
: Not applicable.
: The authors declare no competing interests.
